London--(Marketwire - February 6, 2008) -
Curidium Medica plc ("Curidium" or the "Company")
CURIDIUM TO PRESENT AT THE
10TH ANNUAL BIO CEO & INVESTOR CONFERENCE
London, UK, 6 February 2007, Curidium Medica plc, (LSE: CUR) the
personalized medicine company focused on bringing the right drug to the
right patient, today announced that Executive Chairman, Gosse B.
Bruinsma, M.D. will be presenting at The 10th Annual BIO CEO & Investor
Conference in New York on 12 February at 11:45am Eastern Time in the New
Amsterdam Suite at The Waldorf Astoria Hotel.
Dr. Bruinsma will give an overview of the Company's latest corporate and
commercial developments. The presentation will be webcast live at:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=CUR.L&item_id=1752314.
The webcast will be archived on the Company's website at
http://www.curidium.com.
Ends
For further information, please contact:
Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc
Rob Smith +44 (0)20 7383 5345
Finance Director, Curidium Medica plc
Charlie Cunningham +44 (0)20 7600 1658
JM Finn Capital Markets Ltd
Paula Schwartz +1 917 322 2216
Rx Communications Group
Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics
Notes to Editors
The Bio CEO & Investor Conference
Now in its tenth year, the BIO CEO & Investor Conference is the largest
independent biotechnology investor conference focused on publicly-traded
companies. The conference provides a forum for public and private
investors, research analysts, investment bankers and senior-level
industry executives to discuss investment trends, conduct company
presentations and one-on-one meetings, and learn about investment
opportunities within the biotechnology industry. The conference is
hosted by the Biotechnology Industry Organization (BIO), representing
more than 1,100 biotechnology companies, academic institutions, state
biotechnology centers and related organizations across the United States
and 31 other nations. BIO produces the BIO International Convention, the
world's largest gathering of the biotechnology industry.
Curidium Medica
Curidium is a personalized medicine company identifying targeted
medicines and companion diagnostics to treat patients more effectively.
Curidium's initial focus on diseases of the Central Nervous System has
resulted in the identification of a blood diagnostic test, PsychINDxTM,
which classifies patients with schizophrenia/bipolar disorder into four
subgroups. PsychINDxTM may have the potential to improve the treatment of
patients with schizophrenia/bipolar disorder.
Many chronic human diseases are heterogeneous and their patient
populations consist of mixed subgroups. Through the use of its
proprietary analysis tool, Homomatrix®, Curidium aims to reveal
different patient subgroups characterized by distinct underlying disease
mechanisms potentially leading to the identification of:
1. Diagnostics for better identification and treatment within
heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalized medicines using companion diagnostics and targeted
treatments.
Curidium aims to continue to use this approach to improve patient
treatments in a variety of therapeutic areas. Further information on
Curidium can be found at the Company's website:
www.curidium.com.
Curidium Medica plc (c) 2001-2008. All rights reserved.
Studio 10, Tiger House, London WC1H 9BY, United Kingdom.
Email: info@curidium.com
Tel.: +44 (0)20 7383 5345,
Fax: +44 (0)20 7383 2973
This information is provided by RNS
The company news service from the London Stock Exchange